Advanced Oncotherapy PLC Director/PDMR Shareholding (4971W)
19 August 2020 - 1:30AM
UK Regulatory
TIDMAVO
RNS Number : 4971W
Advanced Oncotherapy PLC
18 August 2020
18 August 2020
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Director/PDMR Shareholding
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that Dr. Michael Sinclair, Executive Chairman, has
purchased a total of 145,000 ordinary shares of 25p each in the
Company ("Ordinary Shares") at an average price of 32.18 pence per
share.
Following these purchases, Dr Sinclair has a total beneficial
interest in 8,280,604 Ordinary Shares, equivalent to 2.70 per cent.
of the Company's issued share capital.
Further details and the information required in accordance with
the requirements of Article 19(3) of the EU Market Abuse Regulation
No 596/2014 are set out at the end of this announcement.
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 (0) 20 3617 8728
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad
& Broker)
Nick Athanas / Liz Kirchner (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Amrit Nahal / Matt Butlin (Sales
& Broking)
FTI Consulting (Financial PR advancedoncotherapy@fticonsulting.com
& IR)
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
Notes for Editors
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
1 Details of the person discharging managerial responsibilities
a) Name Michael Sinclair
-------------------------- ---------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Executive Chairman
-------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Advanced Oncotherapy plc
-------------------------- ---------------------------------------
b) LEI 213800LUDHZOG3YT6C82
-------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------
a) Description of the Ordinary shares of 25p each in
financial instrument, Advanced Oncotherapy plc
type of instrument Identification code (ISIN) for
Identification code Advanced Oncotherapy plc ordinary
shares: GB00BD6SX109
-------------------------- ---------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- ---------------------------------------
c) Price(s) and volume(s) Date Volume Average price
(pence)
17 August
2020 65,000 29.97
------- --------------
18 August
2020 80,000 33.97
------- --------------
-------------------------- ---------------------------------------
d) Aggregated information
- Aggregated volume 145,000 Ordinary Shares
- Price Average price of 32.18 pence
per Ordinary Share
-------------------------- ---------------------------------------
e) Date of the transaction See 4 c) above
-------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange
-------------------------- ---------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBUGDIIDBDGGI
(END) Dow Jones Newswires
August 18, 2020 11:30 ET (15:30 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024